Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nuvalent ( (NUVL) ) has issued an announcement.
On April 7, 2026, Nuvalent, Inc. reported that it had submitted a New Drug Application to the U.S. Food and Drug Administration for neladalkib, a treatment candidate for patients with tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer. The filing marks a key regulatory milestone that could expand treatment options for this heavily pre-treated patient population and strengthen Nuvalent’s position in the targeted lung cancer therapy market if approved.
The most recent analyst rating on (NUVL) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Nuvalent stock, see the NUVL Stock Forecast page.
Spark’s Take on NUVL Stock
According to Spark, TipRanks’ AI Analyst, NUVL is a Neutral.
The score is driven primarily by a strong, debt-free balance sheet that provides funding flexibility, but is materially constrained by the lack of revenue, sharply expanding losses, and accelerating cash burn. Technical indicators are neutral-to-mixed and do not meaningfully offset the fundamental cash flow risk, while valuation metrics provide limited support due to negative earnings and no dividend data.
To see Spark’s full report on NUVL stock, click here.
More about Nuvalent
Nuvalent, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer. Its pipeline includes small-molecule inhibitors designed to address clinically proven oncogenic drivers, with an emphasis on patients whose disease has progressed on prior targeted treatments in defined molecular subsets of lung cancer.
Average Trading Volume: 556,939
Technical Sentiment Signal: Buy
Current Market Cap: $8.15B
Find detailed analytics on NUVL stock on TipRanks’ Stock Analysis page.